This expression frequency is comparable to that reported in hematologic cancers [22,23,24], further supporting the rationale for targeting ROR1 in cancer immunotherapy with minimal immune-related adverse effects. Here, ROR1 is linked to hematopoietic and lymphoid cell neoplasm.